Collects patient data and samples over time in thoracic cancers
Follows adults with lung cancer, collecting questionnaires, tumor tissue and blood samples.
Plain-language title generated from the registry record
Registry title: Prospective Data Collection Initiative on Thoracic Malignancies
Key facts
- Where
- Alkmaar, Amersfoort, Amsterdam, Breda, Delft, Deventer, Ede, Eindhoven, Enschede, Gouda, Groningen, Hilversum, Hoofddorp, Leeuwarden, Maastricht, Nijmegen, Rotterdam, Sittard, The Hague, and Utrecht, NetherlandsSee the 23 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a thoracic cancer, such as lung cancer. It collects health data over time. No set treatment is tested.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A thoracic cancer proven by tissue or cell tests, or strongly suspected after imaging and a team review.
Main reasons for not taking part
- Patients unable to give informed consent because of mental limitations, as decided by the investigator
- Patients unable to give written or electronic informed consent
Read by machine on 12 November 2026.
Where in Netherlands
- Noordwest ZiekenhuisgroepAlkmaar, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Meander MCAmersfoort, NetherlandsContact: F.T.A. van der VeldeTaking people
- NKI-AVLAmsterdam, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Amphia ZiekenhuisBreda, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Reinier de Graaf GasthuisDelft, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Deventer ZiekenhuisDeventer, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Ziekenhuis Gelderse ValleiEde, NetherlandsContact: F.T.A. van der VeldeTaking people
- Máxima MCEindhoven, NetherlandsContact: F.T.A. van der VeldeTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Groene Hart ZiekenhuisGouda, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- UMCGGroningen, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Tergooi MCHilversum, NetherlandsContact: F.T.A. van der VeldeTaking people
- Spaarne GasthuisHoofddorp, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Frisius MCLeeuwarden, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- MUMC+Maastricht, NetherlandsContact: F.T.A. van der VeldeTaking people
- CWZ (Canisius Wilhelmina Ziekenhuis)Nijmegen, NetherlandsContact: F.T.A. van der VeldeTaking people
- RadboudumcNijmegen, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- Erasmus MCRotterdam, NetherlandsContact: F.T.A. van der VeldeTaking people
- ZuyderlandSittard, NetherlandsContact: F.T.A. van der VeldeTaking people
- Haga ZiekenhuisThe Hague, NetherlandsContact: F.T.A. van der VeldeNot yet recruiting
- DiakonessenhuisUtrecht, NetherlandsContact: F.T.A. van der VeldeTaking people
- St Antonius ZiekenhuisUtrecht, NetherlandsContact: F.T.A. van der VeldeTaking people
- UMC UtrechtUtrecht, NetherlandsContact: F.T.A. van der VeldeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dutch Society of Physicians for Pulmonology and Tuberculosis
- Trial code
- NCT06996249
- Record updated
- 7 July 2026
- Original description
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer.Read full original descriptionShow less
Prospective Data Collection Initiative on Thoracic Malignancies - a Prospective Observational Cohort Study
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer.
Although the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of patients with cancer do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications:
1. It is highly desirable to validate the results from clinical trials in the general patient population. This is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters. 2. There is an ever increasing number of therapeutic interventions available for which its efficacy depends on known and unknown tumor-specific, clinical, demographic and other patient characteristics. Large numbers of patients are required to test the relevance of these variables. 3. As a result of rapid technical and drug developments, new minimally invasive treatment options such as stereotactic irradiation or ablation techniques or sublobar resections and new targeted and immunotherapeutic treatments have entered the clinic. These interventions have potentially less side effects compared to the conventional treatments. Still, these new interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) in a real world setting. 4. Many hypotheses related to further optimization of personalized medicine can currently not be tested as they require a large prospective cohort of patients, and a less time-consuming and costly research infrastructure.
A prospective observational cohort study has the potential to fill the gap between prospective randomized trials (efficacy) and patients treated in general practice (effectiveness) and it will enable accrual of clinical trials (innovation).
Inclusion: Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection.
Exclusion: Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator; Inability to provide a written or electronic informed consent.